This assay uses the VM7Luc4E2 cell line [Before June 2016, this cell line was designated as BG1Luc cell line. BG-1 cells were originally described by Geisinger et al. (1998) (12) and were later characterized by researchers at the National Institute of Environmental Health Sciences (NIEHS) (13). Relatively recently, it was discovered that there exist two different variants of BG-1 cells being used by researchers, BG-1 Fr and BG-1 NIEHS. In-depth analysis, including DNA testing, of these two BG-1 variant cell lines carried out by Li and coworkers (2014) (14) showed that the BG-1 Fr was unique and that the BG-1 NIEHS, i.e. the original cell line used to develop the assay, was not the BG1 human ovarian carcinoma cell line, but was instead a variant of the MCF7 human breast cancer cell line. The cell line used in the assay, originally referred to as BG1Luc4E2 (15), will now be designated as VM7Luc4E2 (“V” = variant; “M7” = MCF7 cells). Likewise, the assay will now be designated as the VM7Luc ER TA. While this changes the origin of the cell line upon which the assay is based, it does not affect published validation studies nor the utility and application of this assay for screening of estrogenic/anti-estrogenic chemicals.]. It has been validated by the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), and the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) (1). The VM7Luc cell lines predominantly express endogenous ERα and a minor amount of endogenous ERβ (2) (3) (4).
This assay is applicable to a wide range of substances, provided they can be dissolved in dimethyl sulfoxide (DMSO; CASRN 67-68-5), do not react with DMSO or the cell culture medium, and are not cytotoxic at the concentrations being tested. If use of DMSO is not possible, another vehicle such as ethanol or water may be used (see paragraph 12). The demonstrated performance of the VM7Luc ER TA (ant)agonist assay suggests that data generated with this assay may inform upon ER mediated mechanisms of action and could be considered for prioritisation of substances for further testing.
This assay is specifically designed to detect hER and hERß-mediated TA by measuring chemiluminescence as the endpoint. Chemiluminescence use in bioassays is widespread because luminescence has a high signal-to-background ratio (10). However, the activity of firefly luciferase in cell-based assays can be confounded by substances that inhibit the luciferase enzyme, causing both apparent inhibition or increased luminescence due to protein stabilisation (10). In addition, in some luciferase-based ER reporter gene assays, non-receptor-mediated luminescence signals have been reported at phytoestrogen concentrations higher than 1 μM due to the over-activation of the luciferase reporter gene (9) (11). While the dose-response curve indicates that true activation of the ER system occurs at lower concentrations, luciferase expression obtained at high concentrations of phytoestrogens or similar compounds suspected of producing phytoestrogen-like over-activation of the luciferase reporter gene needs to be examined carefully in stably transfected ER TA assay systems (see Appendix 2).
The “GENERAL INTRODUCTION” and “ER TA ASSAY COMPONENTS” should be read before using this assay for regulatory purposes. Definitions and abbreviations used in this test method are described in Appendix 1.
The assay is used to indicate ER ligand binding, followed by translocation of the receptor-ligand complex to the nucleus. In the nucleus, the receptor-ligand complex binds to specific DNA response elements and transactivates the reporter gene (luc), resulting in the production of luciferase and the subsequent emission of light, which can be quantified using a luminometer. Luciferase activity can be quickly and inexpensively evaluated with a number of commercially available kits. The VM7Luc ER TA utilises an ER responsive human breast adenocarcinoma cell line, VM7, which has been stably transfected with a firefly luc reporter construct under control of four estrogenresponse elements placed upstream of the mouse mammary tumour virus promoter (MMTV), to detect substances with in vitro ER agonist or antagonist activity. This MMTV promoter exhibits only minor cross-reactivity with other steroid and non-steroid hormones (8). Criteria for data interpretation are described in detail in paragraph 41. Briefly, a positive response is identified by a concentration-response curve containing at least three points with non-overlapping error bars (mean ± SD), as well as a change in amplitude (normalised relative light unit [RLU]) of at least 20 % of the maximal value for the reference standard (17-estradiol [E2; CASRN 50-28-2] for the agonist assay, raloxifene HCl [Ral; CASRN 84449-90-1]/E2 for the antagonist assay).
The stably transfected VM7Luc4E2 cell line should be used for the assay. The cell line is currently only available with a technical licensing agreement from the University of California, Davis, California, USA [Michael S. Denison, Ph.D. Professor, Dept. of Environmental Toxicology, 4241 Meyer Hall, One Shields Ave, University of California, Davis, CA 95616, E: msdenison@ucdavis.edu, (530) 754-8649], and from Xenobiotic Detection Systems Inc., Durham, North Carolina, USA [Xenobiotic Detection Systems Inc. 1601 East Geer Street, Suite S, Durham NC, 27704 USA, email: info@dioxins.com, Telephone: 919-688-4804, Fax: 919-688-4404].
To maintain the stability and integrity of the cell line, the cells should be grown for more than one passage from the frozen stock in cell maintenance media (see paragraph 9). Cells should not be cultured for more than 30 passages. For the VM7Luc4E2 cell line, 30 passages will be approximately three months.
Procedures specified in the Guidance on Good Cell Culture Practice (5) (6) should be followed to assure the quality of all materials and methods in order to maintain the integrity, validity, and reproducibility of any work conducted.
VM7Luc4E2 cells are maintained in RPMI 1640 medium supplemented with 0,9 % Pen-Strep and 8.0 % fetal bovine serum (FBS) in a dedicated tissue culture incubator at 37oC ± 1oC, 90 % ± 5 % humidity, and 5,0 % ± 1 % CO2/air.
Upon reaching ~80 % confluence, VM7Luc4E2 cells are subcultured and conditioned to an estrogen-free environment for 48 hours prior to plating the cells in 96-well plates for exposure to test chemicals and analysis of estrogen dependent induction of luciferase activity. The estrogen-free medium (EFM) contains Dulbecco’s Modification of Eagle’s Medium (DMEM) without phenol red, supplemented with 4.5 % charcoal/dextran-treated FBS, 1,9 % L-glutamine, and 0,9 % Pen-Strep. All plasticware should be free of estrogenic activity [see detailed protocol (7)].
Acceptance or rejection of a test is based on the evaluation of reference standard and control results from each experiment conducted on a 96-well plate. Each reference standard is tested in multiple concentrations and thereare multiple samples of each reference and control concentration. Results are compared to quality controls (QC) for these parameters that were derived from the agonist and antagonist historical databases generated by each laboratory during the demonstration of proficiency. The historical databases are updated with reference standard and control values on a continuous basis. Changes in equipment or laboratory conditions may necessitate generation of updated historical databases.
Induction: Plate induction should be measured by dividing the average highest E2 reference standard relative light unit (RLU) value by the average DMSO control RLU value. Five-fold induction is usually achieved, but for purpose of acceptance, induction should be greater than or equal to four-fold.
DMSO control results: Solvent control RLU values should be within 2.5 times the standard deviation of the historical solvent control mean RLU value.
An experiment that fails either acceptance criterion should be discarded and repeated.
It includes acceptability criteria from the agonist range finder test and the following:
Reference standard results: The E2 reference standard concentration-response curve should be sigmoidal in shape and have at least three values within the linear portion of the concentration-response curve.
Positive control results: Methoxychlor control RLU values should be greater than the DMSO mean plus three times the standard deviation from the DMSO mean.
An experiment that fails any single acceptance criterion should be discarded and repeated.
Reduction: Plate reduction is measured by dividing the average highest Ral/E2 reference standard RLU value by the average DMSO control RLU value. Five-fold reduction is usually achieved, but for the purposes of acceptance, reduction should be greater than or equal to three-fold.
E2 control results: E2 control RLU values should be within 2.5 times the standard deviation of the historical E2 control mean RLU value.
DMSO control results: DMSO control RLU values should be within 2.5 times the standard deviation of the historical solvent control mean RLU value.
An experiment that fails any single acceptance criterion will be discarded and repeated.
It includes acceptance criteria from the antagonist range finder test and the following:
Reference standard results: The Ral/E2 reference standard concentration-response curve should be sigmoidal in shape and have at least three values within the linear portion of the concentration-response curve.
Positive control results: Tamoxifen/E2 control RLU values should be less than the E2 control mean minus three times the standard deviation from the E2 control mean.
An experiment that fails any single acceptance criterion will be discarded and repeated.
The vehicle that is used to dissolve the test chemicals should be tested as a vehicle control. The vehicle used during the validation of the VM7Luc ER TA assay was 1 % (v/v) dimethylsulfoxide (DMSO, CASRN 67-68-5) (see paragraph 24). If a vehicle other than DMSO is used, all reference standards, controls, and test chemicals should be tested in the same vehicle, if appropriate.
The reference standard is E2 (CASRN 50-28-2). For range finder testing, the reference standard is comprised of a serial dilution of four concentrations of E2 (1.84 × 10-10, 4,59 × 10-11, 1,15 × 10-11 and 2,87 × 10-12 M), with each concentration tested in duplicate wells.
E2 for comprehensive testing is comprised of a 1:2 serial dilution consisting of 11 concentrations (ranging from 3.67 × 10-10 to 3,59 × 10-13 M) of E2 in duplicate wells.
The reference standard is a combination of Ral (CASRN 84449-90-1) and E2 (CASRN 50-28-2). Ral/E2 for range finder testing is comprised of a serial dilution of three concentrations of Ral (3.06 10-9, 7,67 10-10, and 1,92 10-10M) plus a fixed concentration (9.18 × 10-11 M) of E2 in duplicate wells.
Ral/E2 for comprehensive testing is comprised of a 1:2 serial dilution of Ral (ranging from 2,45 10-8 to 9.57 10-11M) plus a fixed concentration (9.18 × 10-11 M) of E2 consisting of nine concentrations of Ral/E2 in duplicate wells.
The weak positive control is 9,06 10-6 M p,p'-methoxychlor (methoxychlor; CASRN 72-43-5) in EFM.
The weak positive control consists of tamoxifen (CASRN 10540-29-1) 3,36 10-6 M with 9,18 × 10-11 M E2 in EFM.
The E2 control is 9,18 × 10-11 M E2 in EFM and used as a base line negative control.
The induction of luciferase activity of the reference standard (E2) is measured by dividing the average highest E2 reference standard RLU value by the average DMSO control RLU value, and the result should be greater than four-fold.
The mean luciferase activity of the reference standard (Ral/E2) is measured by dividing the average highest Ral/E2 reference standard RLU value by the average DMSO control RLU value and should be greater than three-fold.
Demonstration of Laboratory Proficiency (see paragraph 14 and Tables 3 and 4 in “ER TA ASSAY COMPONENTS” of this test method)
Test chemicals should be dissolved in a solvent that solubilises the test chemical and is miscible with the cell medium. Water, ethanol (95 % to 100 % purity) and DMSO are suitable vehicles. If DMSO is used, the level should not exceed 1 % (v/v). For any vehicle, it should be demonstrated that the maximum volume used is not cytotoxic and does not interfere with the assay performance. Reference standards and controls are dissolved in 100 % solvent and then diluted down to appropriate concentrations in EFM.
The test chemicals are dissolved in 100 % DMSO (or appropriate solvent), and then diluted down to appropriate concentrations in EFM. All test chemicals should be allowed to equilibrate to room temperature before being dissolved and diluted. Test chemical solutions should be prepared fresh for each experiment. Solutions should not have noticeable precipitate or cloudiness. Reference standard and control stocks may be prepared in bulk; however, final reference standard, control dilutions and test chemicals should be freshly prepared for each experiment and used within 24 hours of preparation.
Range finder testing consists of seven point - 1:10 serial dilutions run in duplicate. Initially, test chemicals are tested up to the maximum concentration of 1 mg/ml (~1 mM) for agonist testing and 20 μg/ml (~10 M) for antagonist testing. Range finder experiments are used to determine the following:
Test chemical starting concentrations to be used during comprehensive testing
Test chemical dilutions (1:2 or 1:5) to be used during comprehensive testing
An assessment of cell viability/cytotoxicity is included in the agonist and antagonist assay protocols (7) and is incorporated into range finder and comprehensive testing. The cytotoxicity method that was used to assess cell viability during the validation of the VM7Luc ER TA (1) was a scaled qualitative visual observation method; however, a quantitative method for the determination of cytotoxicity can be used (see protocol (7)). Data from test chemical concentrations that cause more than 20 % reduction in viability cannot be used.
Cells are counted and plated into 96-well tissue culture plates (2 × 105 cells per well) in EFM and incubated for 24 hours to allow the cells to attach to the plate. The EFM is removed and replaced with test and reference chemicals in EFM and incubated for 19-24 hours. Special considerations will need to be applied to those substances that are highly volatile since nearby control wells may generate false positive results. In such cases, “plate sealers” may help to effectively isolate individual wells during testing, and are therefore recommended.
Range finder testing uses all wells of the 96-well plate to test up to six test chemicals as seven point 1:10 serial dilutions in duplicate (see Figures 1 and 2).
Agonist range finder testing uses four concentrations of E2 in duplicate as the reference standard and four replicate wells for the DMSO control.
Antagonist range finder testing uses three concentrations of Ral/E2 with 9,18 × 10-11 M E2 in duplicate as the reference standard, with three replicate wells for the E2 and DMSO controls.
Abbreviations: E2-1 to E2-4 = concentrations of the E2 reference standard (from high to low); TC1-1 to TC1-7 = concentrations (from high to low) of test chemical 1 (TC1); TC2-1 to TC2-7 = concentrations (from high to low) of test chemical 2 (TC2); TC3-1 to TC3-7 = concentrations (from high to low) of test chemical 3 (TC3); TC4-1 to TC4-7 = concentrations (from high to low) of test chemical 4 (TC4); TC5-1 to TC5-7 = concentrations (from high to low) of test chemical 5 (TC5); TC6-1 to TC6-7 = concentrations (from high to low) of test chemical 6 (TC6); VC = vehicle control (DMSO [1 % v/v EFM.]).
Abbreviations: E2 = E2 control; Ral-1 to Ral-3 = concentrations of the Raloxifene/E2 reference standard (from high to low); TC1-1 to TC1-7 = concentrations (from high to low) of test chemical 1 (TC1); TC2-1 to TC2-7 = concentrations (from high to low) of test chemical 2 (TC2); TC3-1 to TC3-7 = concentrations (from high to low) of test chemical 3 (TC3); TC4-1 to TC4-7 = concentrations (from high to low) of test chemical 4 (TC4); TC5-1 to TC5-7 = concentrations (from high to low) of test chemical 5 (TC5); TC6-1 to TC6-7 = concentrations (from high to low) of test chemical 6 (TC6); VC = vehicle control (DMSO [1 % v/v EFM.]).
Note: All test chemicals are tested in the presence of 9,18 × 10 11 M E2.
The recommended final volume of media required for each well is 200 μl. Only use test plates in which the cells in all wells give a viability of 80 % and above.
Determination of starting concentrations for comprehensive agonist testing is described in depth in the agonist protocol (7). Briefly, the following criteria are used:
If there are no points on the test chemical concentration curve that are greater than the mean plus three times the standard deviation of the DMSO control, comprehensive testing will be conducted using an 11-point 1:2 serial dilution starting at the maximum soluble concentration.
If there are points on the test chemical concentration curve that are greater than the mean plus three times the standard deviation of the DMSO control, the starting concentration to be used for the 11-point dilution scheme in comprehensive testing should be one log higher than the concentration giving the highest adjusted RLU value in the range finder. The 11-point dilution scheme will be based on either 1:2 or 1:5 dilutions according to the following criteria:
An 11-point 1:2 serial dilution should be used if the resulting concentration range will encompass the full range of responses based on the concentration response curve generated in the range finder test. Otherwise, use a 1:5 dilution.
If a test chemical exhibits a biphasic concentration response curve in the range finder test, both phases should also be resolved in comprehensive testing.
Determination of starting concentrations for comprehensive antagonist testing is described in depth in the antagonist protocol (7). Briefly, the following criteria are used:
If there are no points on the test chemical concentration curve that are less than the mean minus three times the standard deviation of the E2 control, comprehensive testing will be conducted using an 11-point 1:2 serial dilution starting at the maximum soluble concentration.
If there are points on the test chemical concentration curve that are less than the mean minus three times the standard deviation of the E2 control, the starting concentration to be used for the 11-point dilution scheme in comprehensive testing should be one of the following:
The concentration giving the lowest adjusted RLU value in the range finder
The maximum soluble concentration (See antagonist protocol (7), Figure 14-2)
The lowest cytotoxic concentration (See antagonist protocol (7), Figure 14-3 for a related example).
The 11-point dilution scheme will be based on either a 1:2 or 1:5 serial or dilution according to the following criteria:
An 11-point 1:2 serial dilution should be used if the resulting concentration range will encompass the full range of responses based on the concentration response curve generated in the range finder test. Otherwise a 1:5 dilution should be used.
Comprehensive testing consists of 11-point serial dilutions (either 1:2 or 1:5 serial dilutions based on the starting concentration for comprehensive testing criteria) with each concentration tested in triplicate wells of the 96-well plate (see Figures 3 and 4).
Agonist comprehensive testing uses 11 concentrations of E2 in duplicate as the reference standard. Four replicate wells for the DMSO control and four replicate wells for the methoxychlor control (9.06 × 10-6 M) are included on each plate.
Antagonist comprehensive testing uses nine concentrations of Ral/E2 with 9,18 × 10-11 M E2 in duplicate as the reference standard, with four replicate wells for the E2 9,18 10-11 M control, four replicate wells for DMSO controls, and four replicate wells for tamoxifen 3,36 × 10-6M.
Abbreviations: TC1-1 to TC1-11 = concentrations (from high to low) of test chemical 1; TC2-1 to TC2-11 = concentrations (from high to low) of test chemical 2; E2-1 to E2-11 = concentrations of the E2 reference standard (from high to low); Meth = p,p’ methoxychlor weak positive control; VC = DMSO (1 % v/v) EFM vehicle control
Abbreviations: E2 = E2 control; Ral-1 to Ral-9 = concentrations of the Raloxifene/E2 reference standard (from high to low); Tam = Tamoxifen/E2 weak positive control; TC1-1 to TC1-11 = concentrations (from high to low) of test chemical 1 (TC1); TC2-1 to TC2-11 = concentrations (from high to low) of test chemical 2 (TC2); VC = vehicle control (DMSO [1 % v/v EFM.]).
Note: As noted, all reference and test wells contain a fixed concentration of E2 (9.18 × 10-11 M)
Repeat comprehensive tests for the same chemical should be conducted on different days, to ensure independence. At least two comprehensive tests should be conducted. If the results of the tests contradict each other (e.g. one test is positive, the other negative), or if one of the tests is inadequate, a third additional test should be conducted.
Luminescence is measured in the range of 300 to 650 nm, using an injecting luminometer and with software that controls the injection volume and measurement interval (7). Light emission from each well is expressed as RLU per well.
The EC50 value (half maximal effective concentration of a test chemical [agonists]) and the IC50 value (half maximal inhibitory concentration of a test chemical [antagonists]) are determined from the concentration-response data. For test chemicals that are positive at one or more concentrations, the concentration of test chemical that causes a half-maximal response (IC50 or EC50) is calculated using a Hill function analysis or an appropriate alternative. The Hill function is a four-parameter logistic mathematical model relating the test chemical concentration to the response (typically following a sigmoidal curve) using the equation below:
YBottom
Top Bottom
1 10lgEC50 XHill Slope
Where:
Yresponse (i.e. RLUs);
Xthe logarithm of concentration;
Bottomthe minimum response;
Topthe maximum response;
lg EC50 (or lg IC50)the logarithm of X as the response midway between Top and Bottom;
Hillslopethe steepness of the curve.
The model calculates the best fit for the Top, Bottom, Hillslope, and IC50 and EC50 parameters. For the calculation of EC50 and IC50 values, appropriate statistical software should be used (e.g. Graphpad PrismR statistical software).